10-K: Positron Reports $10.6M Loss Amid PET-CT Expansion & Governance Issues

Positron Corporation reported a significant net loss of $10.6 million for 2025, driven by increased operational costs and an inventory write-down, despite strategic advancements in its PET-CT imaging systems and capital raises.

Summary

• Net loss significantly widened to $10,603,392 in 2025 from $2,379,092 in 2024.
• Revenues decreased by $126,048 to $461,452 in 2025, primarily due to customer transitions from fixed service agreements to time-and-materials in preparation for PET-CT upgrades.
• Cost of sales increased by $1,646,258 to $2,575,742 in 2025, driven by personnel, product testing, new product launch preparation, higher maintenance costs, and a $576,862 inventory write-down.
• General and administrative expenses surged by $6,521,144 to $8,384,173 in 2025, largely due to share-based payments ($4,982,588), expanded sales and marketing, and hardware/software upgrades.
• The company had an accumulated deficit of $144,937,079 as of December 31, 2025.
• Cash and cash equivalents increased to $2,520,466 at December 31, 2025, from $69,791 at December 31, 2024, supported by $10,000,000 from common stock sales.
• Management identified material weaknesses in disclosure controls and internal control over financial reporting, including inadequate segregation of duties and lack of multiple supervision levels.
• The company is pursuing FDA 510(k) clearance for its next-generation Affinity PET-CT 4D 64-slice system, which is currently undergoing safety and performance testing.
• All previously designated series of preferred stock were undesignated effective March 18, 2026, returning 36,750,000 shares to the authorized but unissued preferred stock pool.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly concerning report due to the significant increase in net loss, declining revenue, and explicit "going concern" warning. While strategic initiatives and capital raises offer some positive signals, the material weaknesses in internal controls and pending FDA clearance for key products add substantial uncertainty.

Positives

• Cash and cash equivalents increased significantly to $2,520,466 at December 31, 2025, from $69,791 in 2024, indicating successful capital raising.
• Successfully raised $10,000,000 from sales of common stock in 2025.
• The company is advancing its next-generation Affinity PET-CT 4D 64-slice system, which is undergoing regulatory testing for FDA 510(k) clearance.
• Strategic relationship with Neusoft Medical Systems provides exclusive North American distribution rights for PET, PET-CT, and next-generation PET-CT scanners.
• The market for PET-CT imaging is growing, with the U.S. molecular imaging market projected to reach $4.7 billion by 2032 and the U.S. PET scanner market $870 million by 2030.
• Cardiac PET imaging is increasingly recognized as a superior modality with higher diagnostic accuracy, lower radiation exposure, and higher reimbursement rates compared to SPECT.
• Management is actively pursuing an uplisting to a more prominent public market to enhance visibility and access to capital.
• The company offers flexible financing and access models, including rental and lease-to-own programs, to reduce upfront capital requirements for customers.

Negatives

• Net loss significantly increased to $10,603,392 in 2025 from $2,379,092 in 2024.
• Revenues decreased by $126,048 to $461,452 in 2025.
• Cost of sales increased substantially by $1,646,258, including a $576,862 inventory write-down.
• General and administrative expenses surged by $6,521,144, partly due to $4,982,588 in share-based payments.
• The company has an accumulated deficit of $144,937,079 as of December 31, 2025.
• Management concluded that disclosure controls and internal control over financial reporting were not effective as of December 31, 2025.
• The company has a history of substantial losses and does not expect to generate sufficient revenues and positive cash flows from operations to meet current obligations, raising substantial doubt about its ability to continue as a going concern.
• A significant portion of the $490,000 Non-Recurring Engineering (NRE) fee paid in 2025 is contingent on FDA clearance for a refund of a $1,000,000 deposit, creating financial risk if clearance is not obtained.
• The company repurchased 4,000,000 shares of common stock for $2,500,000 in 2025, which could be seen as a use of capital that might otherwise support operations given the going concern warning.

Risks

• History of substantial losses and no assurance of future profitability.
• Substantial doubt about the company's ability to continue as a going concern.
• Dependence on the continued services of executive officers and key personnel, with significant competition for skilled personnel.
• Potential for continued operating losses and accumulation of deficits, requiring additional financing.
• Increased costs and diversion of management attention due to requirements of being a public reporting company.
• Risk of reduced trading activity if the common stock becomes subject to "penny stock rules" (price below $5.00).
• Failure to maintain effective disclosure controls and internal control over financial reporting due to material weaknesses.
• Volatility in common stock price due to a small number of large stockholders and a thinly traded market.
• Substantial competition from larger multinational OEMs with greater resources and risk of technological obsolescence.
• Impact of a downturn in the U.S. economy on revenues, pricing pressures, and supply chain disruptions.
• Dependence on a limited number of third-party suppliers, including a single contract manufacturer, and the availability of certain radiopharmaceuticals.
• No assurance of market acceptance for new technology, requiring significant capital expenditure from purchasers.
• Risk of competitors infringing on proprietary technology or the company infringing on others' patents, leading to expensive and time-consuming litigation.
• Extensive government regulation (e.g., Medicare, Medicaid, FDA, HIPAA) and the risk of non-compliance leading to penalties or operational curtailment.
• No intention to pay cash dividends in the foreseeable future.

Future Outlook

The company plans to enhance operational execution, scale commercial activities, and expand its market presence in nuclear cardiology through the commercialization of its PET-CT imaging systems. It also intends to enter the oncology imaging market with its next-generation PET-CT systems and pursue strategic partnerships and geographic expansion outside North America. A key capital markets strategy involves pursuing an uplisting to a more prominent public market to improve visibility and access to capital. The company believes that continued advancements in clinical practice, radiopharmaceutical availability, and reimbursement dynamics will support increased utilization of PET-based imaging.

Management Comments

• "We believe that its combined approach to product development, manufacturing, and service enables it to address evolving clinical and operational requirements within nuclear imaging."
• "We believe it is positioned to address growing demand for PET-based imaging solutions across nuclear cardiology and other clinical applications."
• "Management believes that despite our material weaknesses set forth above, our financial statements for the year ended December 31, 2025 are fairly stated, in all material respects, in accordance with U.S. GAAP."
• "Management will continue to monitor and evaluate the effectiveness of our internal controls and procedures and our internal controls over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow."

Industry Context

StockSavvy.ai notes that Positron operates within a dynamic medical technology sector, specifically nuclear imaging, which is undergoing a significant transition from SPECT to PET-CT technologies. This shift is driven by superior diagnostic accuracy, lower radiation exposure, and favorable reimbursement trends for PET imaging, as highlighted by the American Society of Nuclear Cardiology's recommendations and FDA approvals for new radiotracers like Flurpiridaz F-18. While the overall molecular imaging market is projected for steady growth, Positron faces intense competition from industry giants like GE HealthCare, Philips Healthcare, and Siemens Healthineers, who possess significantly greater financial and technical resources. Positron's strategy of offering cost-effective PET-CT systems and integrated support aims to capture market share, particularly among mid-sized hospitals and outpatient centers that may be underserved by larger players. The company's reliance on a single contract manufacturer (Neusoft Medical Systems) for its core imaging systems, while strategic for development, also presents a concentration risk in a competitive and technologically evolving landscape.

Comparison to Industry Standards

• Positron's PET imaging offers enhanced sensitivity and specificity, lower radiation exposure (average 3.7 mSv for cardiac PET MPI vs. 12.8 mSv for SPECT MPI), and the ability to quantify myocardial blood flow, aligning with and often surpassing traditional SPECT imaging capabilities.
• The company's pricing model for PET-CT systems is generally positioned below that of major market participants such as GE HealthCare, Philips Healthcare, and Siemens Healthineers, aiming to make advanced diagnostic imaging more accessible.
• The U.S. molecular imaging market is projected to grow from approximately $2.8 billion in 2024 to $4.7 billion by 2032, and the U.S. PET scanner market from $600 million in 2023 to $870 million by 2030, indicating a favorable growth trajectory for the segment Positron is targeting.
• Positron's installed systems have historically achieved average uptime in excess of 98%, which is a strong operational performance metric for medical imaging equipment.

Corporate Governance

Related Party Transactions

• Issued 8,000,000 shares of common stock to a principal stockholder for $8,000,000 in March 2025.
• Granted 1,500,000 stock options to Adel Abdullah (President and Chairman).
• Granted 750,000 stock options to Aaron Hargrave (Vice President).
• Granted 750,000 stock options to Tis Prager (Director).
• Received $100,000 proceeds from a note payable from a Board Director in February 2025 (Note #4), which was repaid in full during 2025.
• Repaid $150,000 on Note #2 from a Board Director in 2025.
• Repaid $100,000 on Note #3 from a Board Director in 2025.
• Forgave accrued interest of $41,414 on debt held by a Board Director in connection with the repayment of Note #2.
• Note #1, a $1,200,000 debt outstanding at December 31, 2025, is with a Board Director and was extended to June 30, 2026.
• Deposits of $100,000 were paid to Neusoft (strategic partner) for PET-CT systems as of December 31, 2024.
• A $490,000 Non-Recurring Engineering (NRE) fee was paid to the manufacturer (Neusoft Medical Systems) in 2025.

Stakeholder Impact

• Shareholders face significant risk due to recurring losses, going concern doubt, and ineffective internal controls. Dilution risk from potential future capital raises. Potential for increased value if PET-CT systems gain market acceptance and profitability is achieved.
• Employees may experience job insecurity given the going concern warning, but also opportunities for growth and incentives through the equity incentive plan.
• Customers benefit from advanced PET and PET-CT imaging solutions, flexible financing, and comprehensive support services. Potential for improved diagnostic accuracy and patient outcomes.
• Suppliers/Creditors are exposed to risk due to the company's financial instability and going concern doubt. Related party creditors have provided significant financing and have had debt terms extended or interest forgiven.
• Regulatory Authorities will continue to scrutinize the company regarding financial reporting and internal controls, as well as the FDA clearance processes for its products.

Next Steps

• Complete safety and performance testing for the Affinity PET-CT system.
• Pursue regulatory clearance for the Affinity PET-CT system through amendment of its existing U.S. Food and Drug Administration (FDA) 510(k) clearance.
• Further develop and execute business operations, including scaling commercial activities and supporting product deployments.
• Expand presence in nuclear cardiology through commercialization of PET-CT imaging systems.
• Expand into the oncology imaging market with next-generation PET-CT systems.
• Pursue strategic relationships and partnership opportunities.
• Pursue an uplisting to a more prominent public market.
• Implement changes to remediate material weaknesses in internal controls, including adding qualified personnel and implementing ERP modifications by the end of the 2026 fiscal year.

Key Dates

Recommendation

The company reported a substantial increase in net loss, a decrease in revenue, and explicitly stated "substantial doubt about the Company's ability to continue as a going concern." Furthermore, management identified material weaknesses in internal controls and disclosure procedures, indicating significant operational and financial reporting risks. While the company is pursuing strategic initiatives and has raised capital, the fundamental financial performance and governance issues present a high level of risk that outweighs potential future upside, making it a strong sell for seasoned investors.

Keywords

PET-CT imaging, Nuclear cardiology, Medical technology, Diagnostic imaging, Oncology imaging, FDA clearance, SEC filing, Financial losses, Going concern, Internal controls, Share-based compensation, Capital raise, Related party transactions, Healthcare industry, Radiopharmaceuticals